Canexia Health (formerly known as Contextual Genomics), a Vancouver, British Columbia, Canada-based maker of cancer testing for treatment selection and monitoring for all cancer patients, received a new financing round from PacBridge Capital Partners (HK) Limited.
The amount of the deal was not disclosed.
The company intends to use the funds to propel long-term global growth and accelerate its product roadmap.
Led by Michael Ball, CEO, Canexia Health makes high-quality cancer genomic information accessible with clinically-validated assays, informatics, and support. Its suite of genomics-based cancer tests is clinically actionable and cost-effective, designed to improve cancer treatment and monitoring.
In the first half of 2020, the company increased commercial partner agreements with new deal with Genolife, AstraZeneca Canada, the Eastern Ontario Regional Laboratory Association and Queen’s University.
Canexia Health also continues to expand the genomic content of its assays, including MSI and CNV content, as well as recently releasing updates to the Canexia Health Fusions panel. The company has also improved the sensitivity of its liquid biopsy assays for use in monitoring and leveraged tens of thousands of processed samples to improve its AI and machine learning algorithms.